• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
IMM
Click for more information
7.02% 30.5¢

IMMUTEP LIMITED - Announcements

Market Cap $486.6M  ! watchlist Created with Sketch. Add to my watchlist

Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company... Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Announcements


Plus500
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW
TRADE NOW
Plus500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
TRADE NOW

Filter Results
All Price Sensitive Only
search Created with Sketch. Search
search Created with Sketch. Search
IMM Final Director's Interest Notice22/11/17
IMM Final Director's Interest Notice22/11/17
IMM European patent grant for IMP321 in cancerPRICE SENSITIVE22/11/17
IMM Prima changes its name to Immutep Ltd20/11/17
IMM Results of Meeting17/11/17
IMM 2017 AGM CEO Presentation17/11/17
IMM 2017 AGM Chairman's Address17/11/17
IMM Pre-IND meeting with the FDA15/11/17
IMM SITC 2017 Poster Presentation09/11/17
IMM World Immunotherapy Congress 2017 Presentation01/11/17
IMM Warrants Cleansing Prospectuses20/10/17
IMM Dr Triebel presenting at World Immunotherapy Congress 201720/10/17
IMM Annual Report filed on Form 20-F with SEC20/10/17
IMM Notice of Annual General Meeting/Proxy Form17/10/17
IMM Annual Report to shareholders17/10/17
IMM Appendix 4G & Corporate Governance Statement17/10/17
IMM Prima to present at SITC 201717/10/17
IMM Investor Update11/10/17
IMM Appendix 4C - quarterlyPRICE SENSITIVE11/10/17
IMM Change of Director's Interest Notice - Pete Meyers03/10/17
IMM Appendix 3B and Cleansing Notice03/10/17
IMM Japanese Patent Grant for IMP731 AntibodyPRICE SENSITIVE08/09/17
IMM Japanese Patent Grants For IMP321 In Infectious DiseasePRICE SENSITIVE05/09/17
IMM PRR & Monash Uni receive funding grant for LAG-3 ResearchPRICE SENSITIVE30/08/17
IMM Appendix 4E & 2017 Full Year Statutory AccountsPRICE SENSITIVE28/08/17
IMM Appendix 3X21/08/17
IMM Appointment of Non-Executive Director21/08/17
IMM French government research cash rebate of A$1.3M receivedPRICE SENSITIVE16/08/17
IMM Change of Director's Interest Notice07/08/17
IMM Appendix 3B & Cleansing Notice07/08/17
IMM Investor Update03/08/17
IMM Appendix 4C - quarterlyPRICE SENSITIVE18/07/17
IMM Financial UpdatePRICE SENSITIVE18/07/17
IMM 2nd milestone payment to be received from NovartisPRICE SENSITIVE17/07/17
IMM Approvals received to initiate INSIGHT clinical trialPRICE SENSITIVE10/07/17
IMM Cleansing Notice06/07/17
IMM Disclosure Under LR 3.10.5A and 7.1A.4(b)PRICE SENSITIVE06/07/17
IMM Appendix 3B - USD 5 Million Capital Raising04/07/17
IMM Final Prospectus Supplement03/07/17
IMM Form 6-KPRICE SENSITIVE30/06/17
IMM Form 6-KPRICE SENSITIVE30/06/17
IMM USD 5 Million Capital RaisingPRICE SENSITIVE30/06/17
IMM Preliminary Prospectus SupplementPRICE SENSITIVE30/06/17
IMM Operational UpdatePRICE SENSITIVE26/06/17
IMM Expiry of Options07/06/17
IMM IMP321 demonstrates positive safety & efficacy qualitiesPRICE SENSITIVE05/06/17
IMM Prima announces formation of new clinical advisory board01/06/17
IMM AIPAC phase II clinical trial data to be presented at ASCO18/05/17
IMM Approval received to commence 3rd cohort of melanoma trialPRICE SENSITIVE19/04/17
IMM $492k R&D Tax Incentive Refund ReceivedPRICE SENSITIVE12/04/17
IMM Appendix 4C - quarterlyPRICE SENSITIVE12/04/17
IMM Change of Director's Interest Notice - Marc Voigt16/03/17
IMM Appendix 3B & Cleansing Notice16/03/17
IMM PRR completes recruitment for 2nd patient cohortPRICE SENSITIVE15/03/17
IMM S&P DJ Indices Announces March Quarterly RebalancePRICE SENSITIVE10/03/17
IMM Investor Update07/03/17
IMM US patent granted for IMP321PRICE SENSITIVE01/03/17
IMM Half Yearly Report and AccountsPRICE SENSITIVE24/02/17
IMM Operational UpdatePRICE SENSITIVE24/02/17
IMM French Research Tax Credit Payment ReceivedPRICE SENSITIVE13/02/17
IMM Presentation at 2nd Annual Cancer Immunotherapy Conference23/01/17
IMM PRR commences randomised phase IIb clinical trialPRICE SENSITIVE20/01/17
IMM Prima BioMed To Maintain NASDAQ Listing18/01/17
IMM Prima commences recruitment for 2nd cohort of melanoma trialPRICE SENSITIVE12/01/17
IMM Prima January 2017 Corporate Presentation06/01/17
IMM Appendix 4C - quarterlyPRICE SENSITIVE06/01/17
IMM Prima Enters New MTA with CYTLIMICPRICE SENSITIVE05/01/17
IMM Prima announces new LAG-3 agonist antibody product candidatePRICE SENSITIVE03/01/17
IMM Prima announces TACTI-mel clinical trial dataPRICE SENSITIVE29/12/16
IMM Prima announces AIPAC clinical trial dataPRICE SENSITIVE22/12/16
IMM Prima receives UK approval for AIPAC studyPRICE SENSITIVE20/12/16
IMM ADR Ratio Change19/12/16
IMM Change of Director's Interest Notice06/12/16
IMM Appendix 3B06/12/16
IMM Appendix 3B01/12/16
IMM Results of Meeting25/11/16
IMM 2016 AGM CEO Presentation25/11/16
IMM 2016 AGM Address to Shareholders25/11/16
IMM Wuxi & Prima sign MOU for strategic partnershipPRICE SENSITIVE23/11/16
IMM Investor Update11/11/16
IMM Presentation slides for Society for Immunotherapy of Cancer11/11/16
IMM Notice of Annual General Meeting/Proxy Form-PRR.AX 25/10/16
IMM Appendix 4C - quarterly-PRR.AX PRICE SENSITIVE19/10/16
IMM Prima to present at SITC 2016-PRR.AX 13/10/16
IMM Abstracts accepted for poster presentation at ESMO-PRR.AX 06/10/16
IMM Change of Director's Interest Notice-PRR.AX 04/10/16
IMM Appendix 3B & Cleansing Notice-PRR.AX 04/10/16
IMM Annual Report filed on Form 20-F with SEC-PRR.AX 04/10/16
IMM Appendix 4G & Corporate Governance Statement-PRR.AX 28/09/16
IMM Annual Report to shareholders-PRR.AX 28/09/16
IMM Appendix 3B and Cleansing Notice-PRR.AX 02/09/16
IMM Appendix 4E & 2016 Full Year Statutory Accounts-PRR.AX PRICE SENSITIVE31/08/16
IMM European Patent Grants for IMP731 Antibody-PRR.AX PRICE SENSITIVE28/08/16
IMM European Patent Grants for IMP731 Antibody-PRR.AX PRICE SENSITIVE25/08/16
IMM Operational Update-PRR.AX PRICE SENSITIVE18/08/16
IMM Prima Biomed Receives NASDAQ Notice of Bid Price Deficiency-PRR.AX 10/08/16
IMM Appendix 4C - quarterly-PRR.AX PRICE SENSITIVE27/07/16
IMM PRR Collaborates In New Clinical Trial For Imp321-PRR.AX PRICE SENSITIVE12/07/16
IMM First Data From Phase IIb Clinical Trial of Imp321-PRR.AX PRICE SENSITIVE22/06/16
IMM Prima BioMed To Maintain NASDAQ Listing-PRR.AX 07/06/16
IMM Final Director's Interest Notice
22/11/17
IMM Final Director's Interest Notice
22/11/17
IMM European patent grant for IMP321 in cancer
22/11/17PRICE SENSITIVE
IMM Prima changes its name to Immutep Ltd
20/11/17
IMM Results of Meeting
17/11/17
IMM 2017 AGM CEO Presentation
17/11/17
IMM 2017 AGM Chairman's Address
17/11/17
IMM Pre-IND meeting with the FDA
15/11/17
IMM SITC 2017 Poster Presentation
09/11/17
IMM World Immunotherapy Congress 2017 Presentation
01/11/17
IMM Warrants Cleansing Prospectuses
20/10/17
IMM Dr Triebel presenting at World Immunotherapy Congress 2017
20/10/17
IMM Annual Report filed on Form 20-F with SEC
20/10/17
IMM Notice of Annual General Meeting/Proxy Form
17/10/17
IMM Annual Report to shareholders
17/10/17
IMM Appendix 4G & Corporate Governance Statement
17/10/17
IMM Prima to present at SITC 2017
17/10/17
IMM Investor Update
11/10/17
IMM Appendix 4C - quarterly
11/10/17PRICE SENSITIVE
IMM Change of Director's Interest Notice - Pete Meyers
03/10/17
IMM Appendix 3B and Cleansing Notice
03/10/17
IMM Japanese Patent Grant for IMP731 Antibody
08/09/17PRICE SENSITIVE
IMM Japanese Patent Grants For IMP321 In Infectious Disease
05/09/17PRICE SENSITIVE
IMM PRR & Monash Uni receive funding grant for LAG-3 Research
30/08/17PRICE SENSITIVE
IMM Appendix 4E & 2017 Full Year Statutory Accounts
28/08/17PRICE SENSITIVE
IMM Appendix 3X
21/08/17
IMM Appointment of Non-Executive Director
21/08/17
IMM French government research cash rebate of A$1.3M received
16/08/17PRICE SENSITIVE
IMM Change of Director's Interest Notice
07/08/17
IMM Appendix 3B & Cleansing Notice
07/08/17
IMM Investor Update
03/08/17
IMM Appendix 4C - quarterly
18/07/17PRICE SENSITIVE
IMM Financial Update
18/07/17PRICE SENSITIVE
IMM 2nd milestone payment to be received from Novartis
17/07/17PRICE SENSITIVE
IMM Approvals received to initiate INSIGHT clinical trial
10/07/17PRICE SENSITIVE
IMM Cleansing Notice
06/07/17
IMM Disclosure Under LR 3.10.5A and 7.1A.4(b)
06/07/17PRICE SENSITIVE
IMM Appendix 3B - USD 5 Million Capital Raising
04/07/17
IMM Final Prospectus Supplement
03/07/17
IMM Form 6-K
30/06/17PRICE SENSITIVE
IMM Form 6-K
30/06/17PRICE SENSITIVE
IMM USD 5 Million Capital Raising
30/06/17PRICE SENSITIVE
IMM Preliminary Prospectus Supplement
30/06/17PRICE SENSITIVE
IMM Operational Update
26/06/17PRICE SENSITIVE
IMM Expiry of Options
07/06/17
IMM IMP321 demonstrates positive safety & efficacy qualities
05/06/17PRICE SENSITIVE
IMM Prima announces formation of new clinical advisory board
01/06/17
IMM AIPAC phase II clinical trial data to be presented at ASCO
18/05/17
IMM Approval received to commence 3rd cohort of melanoma trial
19/04/17PRICE SENSITIVE
IMM $492k R&D Tax Incentive Refund Received
12/04/17PRICE SENSITIVE
IMM Appendix 4C - quarterly
12/04/17PRICE SENSITIVE
IMM Change of Director's Interest Notice - Marc Voigt
16/03/17
IMM Appendix 3B & Cleansing Notice
16/03/17
IMM PRR completes recruitment for 2nd patient cohort
15/03/17PRICE SENSITIVE
IMM S&P DJ Indices Announces March Quarterly Rebalance
10/03/17PRICE SENSITIVE
IMM Investor Update
07/03/17
IMM US patent granted for IMP321
01/03/17PRICE SENSITIVE
IMM Half Yearly Report and Accounts
24/02/17PRICE SENSITIVE
IMM Operational Update
24/02/17PRICE SENSITIVE
IMM French Research Tax Credit Payment Received
13/02/17PRICE SENSITIVE
IMM Presentation at 2nd Annual Cancer Immunotherapy Conference
23/01/17
IMM PRR commences randomised phase IIb clinical trial
20/01/17PRICE SENSITIVE
IMM Prima BioMed To Maintain NASDAQ Listing
18/01/17
IMM Prima commences recruitment for 2nd cohort of melanoma trial
12/01/17PRICE SENSITIVE
IMM Prima January 2017 Corporate Presentation
06/01/17
IMM Appendix 4C - quarterly
06/01/17PRICE SENSITIVE
IMM Prima Enters New MTA with CYTLIMIC
05/01/17PRICE SENSITIVE
IMM Prima announces new LAG-3 agonist antibody product candidate
03/01/17PRICE SENSITIVE
IMM Prima announces TACTI-mel clinical trial data
29/12/16PRICE SENSITIVE
IMM Prima announces AIPAC clinical trial data
22/12/16PRICE SENSITIVE
IMM Prima receives UK approval for AIPAC study
20/12/16PRICE SENSITIVE
IMM ADR Ratio Change
19/12/16
IMM Change of Director's Interest Notice
06/12/16
IMM Appendix 3B
06/12/16
IMM Appendix 3B
01/12/16
IMM Results of Meeting
25/11/16
IMM 2016 AGM CEO Presentation
25/11/16
IMM 2016 AGM Address to Shareholders
25/11/16
IMM Wuxi & Prima sign MOU for strategic partnership
23/11/16PRICE SENSITIVE
IMM Investor Update
11/11/16
IMM Presentation slides for Society for Immunotherapy of Cancer
11/11/16
IMM Notice of Annual General Meeting/Proxy Form-PRR.AX
25/10/16
IMM Appendix 4C - quarterly-PRR.AX
19/10/16PRICE SENSITIVE
IMM Prima to present at SITC 2016-PRR.AX
13/10/16
IMM Abstracts accepted for poster presentation at ESMO-PRR.AX
06/10/16
IMM Change of Director's Interest Notice-PRR.AX
04/10/16
IMM Appendix 3B & Cleansing Notice-PRR.AX
04/10/16
IMM Annual Report filed on Form 20-F with SEC-PRR.AX
04/10/16
IMM Appendix 4G & Corporate Governance Statement-PRR.AX
28/09/16
IMM Annual Report to shareholders-PRR.AX
28/09/16
IMM Appendix 3B and Cleansing Notice-PRR.AX
02/09/16
IMM Appendix 4E & 2016 Full Year Statutory Accounts-PRR.AX
31/08/16PRICE SENSITIVE
IMM European Patent Grants for IMP731 Antibody-PRR.AX
28/08/16PRICE SENSITIVE
IMM European Patent Grants for IMP731 Antibody-PRR.AX
25/08/16PRICE SENSITIVE
IMM Operational Update-PRR.AX
18/08/16PRICE SENSITIVE
IMM Prima Biomed Receives NASDAQ Notice of Bid Price Deficiency-PRR.AX
10/08/16
IMM Appendix 4C - quarterly-PRR.AX
27/07/16PRICE SENSITIVE
IMM PRR Collaborates In New Clinical Trial For Imp321-PRR.AX
12/07/16PRICE SENSITIVE
IMM First Data From Phase IIb Clinical Trial of Imp321-PRR.AX
22/06/16PRICE SENSITIVE
IMM Prima BioMed To Maintain NASDAQ Listing-PRR.AX
07/06/16
refresh Created with Sketch. REFRESH
 
(20min delay)
Last
30.5¢ 		Change
0.020(7.02%) 		Mkt cap ! $486.6M
Open High Low Value Volume
29.0¢ 31.0¢ 29.0¢ $1.171M 3.900M

Buyers (Bids)

No. Vol. Price($)
5 101067 30.5¢
 

Sellers (Offers)

Price($) Vol. No.
31.0¢ 8068 2
View Market Depth
Last trade - 16.10pm 22/11/2024 (20 minute delay) ?
Last
30.5¢ 		  Change
0.020 ( 4.85 %)
Open High Low Volume
29.0¢ 31.0¢ 29.0¢ 1352108
Last updated 15.59pm 22/11/2024 ?
IMM (ASX) Chart

Top Stories

Sales growth pushes Lovisa's fortunes (and shares) upwards

Lovisa Holdings Ltd has seen its shares rise more than 2% following a sales update, and on a good day for the consumer discretionary sector
Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing Bigtincan Holdings has fielded an offer from Investcorp. But if you think it's underwhelming – consider Wall Street volumes.
To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels Put simply: if 3D Printing is a gold rush, Amaero is selling shovels. Or maybe it's more like sneakers in an arms race.
HotCopper Highlights: Your most watched stocks for Week 47, 2024 In this segment we’ll look at the top stocks HotCopper users have been watching, and discussing, through Week 47. Let’s get into it. 
Scientific conference spotlights PYC's work on blindness disease treatment PYC Therapeutics Ltd will have data from its ongoing trial into a drug candidate to treat Retinitis Pigmentosa type 11 presented in Singapore
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.